Good decisions require good information

Find hidden gems and smart strategies from top experts when you join Seeking Alpha.

AUPH Aurinia Pharmaceuticals Inc.
Stock Price & Overview

$5.61-0.25 (-4.27%)4:00 PM 07/12/24
NASDAQ | $USD | Post-Market: $5.61 7:58 PM

Charts

EPS
PE
Div Rate
Yield
Short Interest
Market Cap
Volume
Prev. Close

Quant Ranking

Ratings Summary

People Also Follow

Similar to AUPH

ETFs Holding AUPH

AUPH Company Profile

Aurinia Pharmaceuticals Inc. logo
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Employees
300
Founded
1993
Address
  • 118 Avenue , 14315
  • Suite 140
  • Edmonton, AB, T5L 4S6
  • Canada
Phone Number
250 744 2487

AUPH Revenue

AUPH Earnings Per Share

Earnings Estimates

Earnings Revisions

Valuation

Growth

Profitability

Momentum

Capital Structure

Dividends

AUPH does not currently pay a dividend.

AUPH Ownership

AUPH Peers

Risk

Technicals

AUPH Transcripts

Investor Presentations

AUPH SEC Filings

AUPH Income Statement

AUPH Balance Sheet

AUPH Cash Flow Statement

AUPH Long Term Solvency

Discover More

You may be interested in:

Aurinia Pharmaceuticals Inc. (AUPH) Frequently Asked Questions

People Also Follow

Similar to AUPH

ETFs Holding AUPH